GuidelineJournal of the American Academy of Dermatology2021
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.
Guideline in Journal of the American Academy of Dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- Communication to promote and support physical distancing for COVID-19 prevention and control: a rapid reviewThe Cochrane database of systematic reviews · 2023Pooled it
- A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders.Dermatologic therapy · 2022Pooled it
- Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- Global Comparison of COVID-19 Vaccination Rates among Psoriasis Patients.Life (Basel, Switzerland) · 2024Article
- Management of Psoriasis Patients with Serious Infectious Diseases.Advances in therapy · 2024Review
- Article
- Psoriasis and biological drugs at the time of SARS-CoV-2 infection: a mini review outlining risk of infection, seroprevalence, and safety and efficacy of the BNT162b2 vaccine.Frontiers in immunology · 2024Review
- Experiences of Dermatologists and Patients Regarding Psoriasis and Its Connection to Psoriatic Arthritis in Saudi Arabia.Psoriasis (Auckland, N.Z.) · 2024Article
- COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study.Infectious diseases & clinical microbiology · 2023Article
- Psoriasis flares after COVID-19 vaccination: adherence to biologic therapy reduces psoriasis exacerbations: a case-control study.Clinical and experimental vaccine research · 2023Article
- Management of Infections in Psoriatic Patients Treated with Systemic Therapies: A Lesson from the Immunopathogenesis of Psoriasis.Dermatology practical & conceptual · 2023Review
- Biologics targeting IL-17 and IL-23 maintain stability in patients with psoriasis during COVID-19 infection: a case-control study.Frontiers in medicine · 2023Article
- The Relationship Between Psoriasis, COVID-19 Infection and Vaccination During Treatment of Patients.Advances in experimental medicine and biology · 2023Article
- Serum vitamin D levels can be predictive of psoriasis flares up after COVID-19 vaccination: a retrospective case control study.Frontiers in medicine · 2023Article
- COVID vaccine recommendations in dermatologic patients on immunosuppressive agents: Lessons learned from pandemic.Journal of cosmetic dermatology · 2022Review
- COVID-19 Knowledge in Patients with Psoriasis Receiving Systemic Therapy: a Questionnaire Study.Dermatology practical & conceptual · 2022Article
- Inflammation Causes Exacerbation of COVID-19: How about Skin Inflammation?International journal of molecular sciences · 2022Review
- Erythrodermic psoriasis after COVID-19 vaccination.JAAD case reports · 2022Article
- Public Perception of SARS-CoV-2 Vaccines Among Psoriasis Patients in Social Media: Content, Sentiment, and Engagement Analysis.Journal of psoriasis and psoriatic arthritis · 2022Article
- COVID-19 outcomes in patients with psoriasis and psoriatic arthritis: A prospective cohort study.JAAD international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 16 institutions in 2 countries.
Funding
Abstract
objectiveTo update guidance regarding the management of psoriatic disease during the COVID-19 pandemic. STUDY
designThe task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation staff. Clinical questions relevant to the psoriatic disease community were informed by inquiries received by the National Psoriasis Foundation. A Delphi process was conducted.
resultsThe TF updated evidence for the original 22 statements and added 5 new recommendations. The average of the votes was within the category of agreement for all statements, 13 with high consensus and 14 with moderate consensus. LIMITATIONS: The evidence behind many guidance statements is variable in quality and/or quantity.
conclusionsThese statements provide guidance for the treatment of patients with psoriatic disease on topics including how the disease and its treatments affect COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 (including novel vaccination), and what they should do if they develop COVID-19. The guidance is a living document that is continuously updated by the TF as data emerge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.